Author: Zacks Small Cap Research

1424344454655440 / 548 POSTS
OTC:BSGMIn the last 3 months there have been 18 Open Market Buys recorded with the SEC regarding Insider Activity for BioSig Technologies (OTC:BSGM). Director Patrick Joseph Gallagher bought 20,000 shares of BioSig Technologies stock in a transaction ...
By Brian Marckx, CFANASDAQ:GNMXAevi (NASDAQ:GNMX) reported financial results for their fourth quarter on March 13th.  The operational update covered the two AEVI-001 programs (ADHD and ASD), AEVI-002 anti-LIGHT in pediatric Crohn’s and the first gli ...
By Brian Marckx, CFANASDAQ:GNMXAevi (NASDAQ:GNMX) reported financial results for their fourth quarter on March 13th.  The operational update covered the two AEVI-001 programs (ADHD and ASD), AEVI-002 anti-LIGHT in pediatric Crohn’s and the first gli ...
By Anita Dushyanth, PhD NASDAQ:PULMFinancial Update:On March 13, 2018 Pulmatrix (NASDAQ:PULM) reported financial results for fiscal 2017.Cystic Fibrosis Foundation Therapeutics (CFFT) is a nonprofit drug discovery and development affiliate of the Cys ...
By David Bautz, PhDTSX:ATE.VOn March 20, 2018, Antibe Therapeutics Inc. (TSX:ATE.V) announced positive topline results for the Phase 2 gastrointestinal (GI) safety study of its lead drug, ATB-346. The double-blind, gastrointestinal (GI) safety study ...
By Steven Ralston, CFANASDAQ:DSKE SUMMARY OF RECENT EVENTS• On March 16, 2018, Daseke (NASDAQ:DSKE) announced financial results for the full year of 2017 • Total revenues increased 29.8% to $846.3 million, primarily due to the seven ...
OTC:AXIMSummary• AXIM Biotechnologies (OTC:AXIM) holds the intellectual property rights to the controlled-release, trans-mucosal (chewing gum) drug delivery platform for medical cannabinoids. o The company is pursuing several indications: • Irritable ...
By David Bautz, PhDNASDAQ:TNXPBusiness UpdateHONOR Study Nearing 50% EnrollmentIn 2017, Tonix (NASDAQ:TNXP) announced the first patient was enrolled in the Phase 3 HONOR study of TNX-102 SL 5.6 mg for the treatment of posttraumatic stress disorder (P ...
By John Vandermosten, CFANASDAQ:CRMEFor its fourth quarter and full year, Cardiome Pharma Corp (NASDAQ:CRME) reported revenues of $7.0 million and $24.0 million respectively, a (0.3%) and (5.1%) decline.  Fourth quarter net loss was ($8.3) million or ...
By Brian Marckx, CFANASDAQ:CTSOCytoSorbents (NASDAQ:CTSO) reported financial results for their fourth quarter ending December 31st and provided a business update.  Product sales continue their regular and rapid climb upward, setting another record an ...
1424344454655440 / 548 POSTS